Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is an early stage drug development company with a specific focus on Alzheimer's disease, which we believe presents a significant market opportunity. The company recently reported positive interim results for its Phase 2 trial for IGC-AD1, and we expect additional positive data and milestone progress to be catalysts for the stock. However, there are risks to our outlook, including balance sheet/liquidity risks, product failure in clinical trials, and regulatory and commercialization hurdles.

Bears say

IGC Pharma is a clinical-stage pharmaceutical company with a primary focus on developing cannabinoid-based formulations for various diseases and conditions, including Alzheimer's disease. Despite the positive interim results from their Phase 2 trial and upcoming milestones, the company's small revenue and recent change in fiscal year end raise concerns about their financial stability. Additionally, while their investigational drug IGC-AD1 has shown promise in preclinical studies, there is still a need for more rigorous clinical trials before it can be considered an effective treatment for Alzheimer's disease.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.